Small Cap Rise Ends Amid Quiet AIM Week

Clean Power Hydrogen Faces Major Setbacks

Shares in Clean Power Hydrogen experienced a dramatic decline this week, plummeting by 90 per cent. This sharp drop marks the consequences of issues that originated in late May when its hydrogen electrolyser failed during factory acceptance testing. The damage was so severe that the unit was deemed irreparable. As a result, a planned fundraising effort was abandoned, and the associated contract was terminated.

Despite these challenges, the company has managed to secure new investment of up to £7.5 million. However, this funding came at a significant discount. New shares were issued at 1.5p each, which is a substantial reduction from the previous trading price of 13.6p. Alongside the capital injection, there was a reshuffling of the board as Clean Power shifts its focus towards a more capital-light model centered on licensing its proprietary membrane-free electrolyser technology. While the exact implications of this pivot remain unclear, it represents a strategic move for the company.

The overall experience has been a difficult one for all involved. However, there is a small silver lining: management is working with insurers to assess a potential claim and explore the possibility of an interim payment.

Wider Market Trends

Turning to the broader market, the AIM All-Share index saw its two-week winning streak come to an end. The index fell by 1.6 per cent to 765.13, reflecting a relatively dull week for small-cap news. The FTSE 100 also declined, dropping by 1.8 per cent.

There was another wave of fundraising activities before the City enters its traditional summer lull. In some cases, the mark-downs were particularly harsh, and the theory that a short, sharp shock to share prices can lead to long-term value creation does not always hold true.

Fundraising Efforts Continue

EnSilica, a company that designs chips for satellite communications, industrial, and healthcare industries, launched the most ambitious fundraising round of the week. It raised approximately £14 million through an oversubscribed placing and subscription, providing fresh capital to accelerate product development and expand its contract pipeline. Despite the successful fundraising, the company’s shares ended the week slightly lower by 3 per cent.

Phoenix Copper, which fell by 58 per cent, raised £2.1 million net to repay its short-term debt facility and fund process design engineering. Quadrise, focused on developing a green fuel additive for the shipping industry, launched a £2.4 million fundraising round to support commercial marine trials with MSC and Cargill, including work towards a supply hub in Antwerp. The stock fell 42 per cent.

GoldStone Resources was an exception, rising by 23 per cent after securing £3.51 million from Persistence Gold Group, which took a 20.96 per cent stake at 1p per share. The proceeds will be used to expand drilling at the Homase mine in Ghana, grow the resource base, and bolster working capital.

Takeover Talks Drive Gains

Safestay saw a significant surge in its share price, rising by 122 per cent after confirming talks with Infill Capital Partners over a possible £41 million take-private offer. The approach may include a cash offer and an unlisted share alternative.

Victoria also experienced a strong performance, with its shares rising by 25 per cent after agreeing to a refinancing deal that significantly reduced its senior secured debt and preferred share liabilities. Insig AI added 20 per cent after its chief executive proposed investing £250,000 at 15p per share, a premium to the market price. The data analytics firm expects revenue to more than double to £1.65 million in financial year 2027.

IXICO Steadily Advances

IXICO, a neuroscience imaging specialist, quietly continued its progress away from the spotlight. Its shares rose by 8 per cent to 9.15p this week after it lifted its revenue guidance for the year. The company now expects at least £8 million, a 22 per cent increase compared to the previous year, surpassing market expectations.

The AI-driven contract research group attributed the improved performance to contract extensions and a broader client base. Chief executive Bram Goorden stated that the results validate a strategy launched in 2024. Broker Cavendish believes the new TechBio strategy can deliver high-margin, recurring revenues alongside the established imaging business. Its price target is 26p, nearly three times the current share price.

Share :